


EVOLVE-MI: EVOLocumab Very Early after MI – Study Design

~3.5 Year Median Follow Up



1° endpoint: total (first and subsequent) MI, ischemic stroke, any arterial revascularization, all-cause death

- Evolocumab dosed within 10 days of index MI. Home delivery and self-administration of drug
- **Pragmatic data collection through EMR, patient- or coordinator-completed eCRF and national registries (in Sweden)**

eCRF electronic case report form, EMR electronic medical record, NSTEMI non-ST elevation myocardial infarction, STEMI ST elevation myocardial infarction

